First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
TRAX Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
First Tracks Biotherapeutics IncNASDAQ: TRAX
Total Equity · Q1 FY2026 · quarter ended Mar 2026
Total equity falls 34.3% from a year ago
Total equity stood at $257.46M at the end of Q1 FY2026, down 34.3% from a year earlier.
Context
- Total equity amounted to 88.6% of total assets at the end of Q1 FY2026.
- Total equity increased in 0 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -34.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 287.49M USD
- Year-over-year change
- -26.6%
- 2-year CAGR
- -16.2%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 287.49M | -26.6% |
| FY2024 | 2024-12-31 | 391.6M | -4.5% |
| FY2023 | 2023-12-31 | 409.85M | — |
Total Equity vs competitors
How TRAX compares with its peers on the latest reported figures
- TRAX's Mar 2026 total equity of $257.46M is the 2nd highest of the 10 companies compared; the peer median is $148.09M.
- Its year-over-year change of -34.3% is the 7th highest of 9, against a peer median of -6.3%.
- Total equity amounts to 88.6% of total assets for TRAX, versus a peer median of 79.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $656.95M | +26.4% | +33.0% | 86.3% | |
TRAXFirst Tracks Biotherapeutics Inc | Mar 2026 | $257.46M | -34.3% | — | 88.6% |
| Mar 2026 | $254.02M | -38.4% | +64.2% | 63.4% | |
| Jun 2026 | $214.79M | +1687.5% | +69.6% | 90.2% | |
| Mar 2026 | $151.23M | +2960.5% | — | 79.7% | |
CLYMClimb Bio, Inc. | Mar 2026 | $148.09M | -23.4% | +7.6% | 97.2% |
| Mar 2026 | $143.65M | -0.3% | -19.5% | 72.3% | |
| Jun 2026 | $112.77M | — | — | 87.9% | |
| Mar 2026 | $100.46M | -12.3% | -1.2% | 68.5% | |
| Mar 2026 | $12.75M | -62.5% | -47.8% | 3.9% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding TRAX) | $148.09M | -6.3% | +7.6% | 79.7% | |
Competitors are the stored peer set for TRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
First Tracks Biotherapeutics Inc
NASDAQ:TRAX
Intrinsic Alpha fair value
Locked
Current Price
$44.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.